Catapult Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Catapult Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-15,000	Closed	-$2.71M	–	248
2015 Q2	$2.71M	Sell	15,000 -7,500	-33%	-$1.29M	0.39%	85
2015 Q1	$3.9M	Buy	+22,500	New	+$4.07M	0.48%	67
2013 Q4	–	Sell	-15,000	Closed	-$1.74M	–	275
2013 Q3	$1.74M	Buy	+15,000	New	+$1.65M	0.22%	144

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catapult Capital Management's ALXN Position: Q3 2015 in Review

Catapult Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 15,000 shares — an estimated $2.71M sold.

Catapult Capital Management first reported a position in ALXN in Q3 2013 and held it in 3 quarters. The position peaked at $3.9M in Q1 2015. 514 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

Catapult Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Catapult Capital Management sold 15,000 Alexion Pharmaceuticals shares in Q3 2015, an estimated $2.71M.
Catapult Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 3 quarters.
Catapult Capital Management's Alexion Pharmaceuticals position peaked at $3.9M in Q1 2015.
514 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.